The Latest Breaking News from Barchart

Analysts have been raising their price targets on Salesforce stock. This is despite CRM stock having been flat over the last month. One of the best plays here is to sell short out-of-the-money puts for income.

vTv Therapeutics (VTVT) is a $156 million biopharma focused on small molecule drugs for Alzheimer’s, diabetes, and inflammatory disorders, all in clinical trials. VTVT has surged 182% over the past year, hitting a two-year high, with strong technical momentum. Wall Street leans “Strong Buy” with targets up to $47, but...

Chubb (CB) is trading at new 20-year highs and has strong technical momentum. Shares are up 13% over the past year, making it a slow-and-steady insurance stock. CB maintains a 100% technical “Buy” opinion from Barchart. Analysts and individual investors are largely bullish on the stock with price targets as...

Alphabet, Inc. is set to announce earnings early next month. Whether GOOGL stock rises or stays flat, investors can make a 2.0% income yield by shorting one-month out-of-the-money put options.

Ekso Bionics stock soars as Applied Digital announces plans of spinning off its cloud business. Here’s how you should play EKSO shares heading into 2026.

This gold miner stock's strong fundamentals put it at the top of the list.

I discussed Occidental Petroleum's possible dividend hike next month in my Dec. 23, 2025, Barchart article. I showed that OXY stock could be worth $50. Investors are now piling into January 16, 2026, expiry call options.

Puma Biotechnology (PBYI) relies on one product. It has weak fundamentals and has struggled to grow sales. PBYI stock has surged 91% over the past year, driven by technical momentum and speculative trading spikes. Despite technical “Buy” signals, analyst sentiment is mixed, with most rating PBYI as “Hold” or “Sell.”...

While Ford is up 34% for the year and has a healthy dividend yield of 4.5%, the stock's 2026 forecast does not look too bright.